首页> Japanese journal of clinical oncology> HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.

HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.

导出原文传递

翻译打印收藏纠错

第一作者： Weiwei,Xu

第一单位： Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.

作者： Weiwei,Xu ^[1] ; Yunshan,Jiang ^[1] ; Lingyun,Xu ^[2] ; Changwen,Li ^[3] ; Ji,Wang ^[1] ; Zhao,Liu ^[4] ; Dandan,Xue ^[5] ; Yanlin,Gu ^[6] ; Zhaoyun,Zhong ^[1] ; Shiqing,He ^[4] ; Shui,Wang ^[1] ; Wenbin,Zhou ^[1] ; Hong,Pan ^[1]

作者单位： Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China. ^[1] Department of Breast Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China. ^[2] Department of Breast Surgery, Xuzhou Central Hospital, XuZhou Clinical School of Xuzhou Medical University, Xuzhou, China. ^[3] Department of Thyroid and Breast Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. ^[4] Department of Thyroid and Breast Surgery, The Affiliated Hospital of Nantong University, Nantong, China. ^[5] Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China. ^[6]

关键词 HER2-low breast cancer neoadjuvant chemotherapy pathological response prognosis